Research graph
References from Progression‐free survival and overall survival in the first‐line treatment of BRCA wild‐type advanced epithelial ovarian cancer: An analysis of patient‐level data pooled from historical clinical trials. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer Stat Facts: Ovarian Cancer
2026 · External reference
Unresolved reference
External reference
10.3322/caac.21559
10.3322/caac.21559 · External reference
10.1158/1940‐6207.capr‐19‐0184
10.1158/1940‐6207.capr‐19‐0184 · External reference
Unresolved reference
External reference
Update on the role of surgery in the management of advanced epithelial ovarian cancer
2020 · External reference
10.1093/annonc/mdx441
10.1093/annonc/mdx441 · External reference
10.1155/2014/953509
10.1155/2014/953509 · External reference
10.1038/nature10166
10.1038/nature10166 · External reference
10.1158/1078‐0432.ccr‐13‐2287
10.1158/1078‐0432.ccr‐13‐2287 · External reference
10.1200/jco.19.01009
10.1200/jco.19.01009 · External reference
10.1016/s1470‐2045(15)00086‐8
10.1016/s1470‐2045(15)00086‐8 · External reference
10.1634/theoncologist.13‐s2‐19
10.1634/theoncologist.13‐s2‐19 · External reference
10.1097/ppo.0b013e3181b9c602
10.1097/ppo.0b013e3181b9c602 · External reference
10.1136/ijgc‐2023‐004487
10.1136/ijgc‐2023‐004487 · External reference
10.1007/s12032‐017‐0939‐9
10.1007/s12032‐017‐0939‐9 · External reference
Correlation of progression‐free and post‐progression survival with overall survival in phase III trials of first‐line chemotherapy for advanced epithelial ovarian cancer
2015 · External reference
10.1177/1758835918788500
10.1177/1758835918788500 · External reference
10.1186/s12957‐023‐03027‐4
10.1186/s12957‐023‐03027‐4 · External reference
10.1007/s12350‐019‐01624‐z
10.1007/s12350‐019‐01624‐z · External reference
10.1158/1078‐0432.ccr‐17‐1327
10.1158/1078‐0432.ccr‐17‐1327 · External reference
10.1016/j.ijgc.2025.101704
10.1016/j.ijgc.2025.101704 · External reference
10.1158/1078‐0432.ccr‐19‐0226
10.1158/1078‐0432.ccr‐19‐0226 · External reference
10.1056/nejmoa1103799
10.1056/nejmoa1103799 · External reference
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non‐BRCA‐mutated advanced ovarian cancer
2025 · External reference
10.1200/jco.22.01549
10.1200/jco.22.01549 · External reference
10.1016/j.ejca.2023.04.024
10.1016/j.ejca.2023.04.024 · External reference
10.1016/j.annonc.2024.08.2241
10.1016/j.annonc.2024.08.2241 · External reference
10.1016/j.annonc.2023.05.005
10.1016/j.annonc.2023.05.005 · External reference
10.1038/nrclinonc.2010.43
10.1038/nrclinonc.2010.43 · External reference
10.1002/pst.1812
10.1002/pst.1812 · External reference
10.7150/jca.32205
10.7150/jca.32205 · External reference
10.1001/jamanetworkopen.2019.18939
10.1001/jamanetworkopen.2019.18939 · External reference
10.1200/jco.23.00225
10.1200/jco.23.00225 · External reference
10.1007/s43441‐025‐00911‐x
10.1007/s43441‐025‐00911‐x · External reference
Unresolved reference
External reference
Unresolved reference
External reference
